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The objective of the present research was to evaluate the usefulness of anti-cyclic citrullinated peptide (anti-CCP) antibodies and
the IgM rheumatoid factor (IgM RF) test for the differential diagnosis of leprosy with articular involvement and rheumatoid arthritis
(RA). Anti-CCP antibodies and IgM RF were measured in the sera of 158 leprosy patients (76 with and 82 without articular
involvement), 69 RA patients and 89 healthy controls. Leprosy diagnosis was performed according to Ridley and Jopling
classification criteria and clinical and demographic characteristics of leprosy patients were collected by a standard question-
naire. Leprosy patients with any concomitant rheumatic disease were excluded. Serum samples were obtained from all
participants and frozen at –20°C. Measurement of anti-CCP antibodies and IgM RF were performed by ELISA, using a
commercial second-generation kit, and the latex agglutination test, respectively. Anti-CCP antibodies and IgM RF were detected
in low frequencies (2.6 and 1.3%, respectively) in leprosy patients and were not associated with articular involvement. Among
healthy individuals both anti-CCP antibodies and IgM RF were each detected in 3.4% of the subjects. In contrast, in the RA group,
anti-CCP antibodies were present in 81.2% and IgM RF in 62.3%. In the present study, both anti-CCP antibodies and IgM RF
showed good positive predictive value for RA, helping to discriminate between RA and leprosy patients with articular
involvement. However, anti-CCP antibodies were more specific for RA diagnosis in the population under study.
Key words: Leprosy; Rheumatoid arthritis; Anti-cyclic citrullinated peptide antibodies; Rheumatoid factor
Publication supported by FAPESP.
Received April 22, 2008. Accepted November 7, 2008
Introduction
Leprosy is a chronic granulomatous disease caused by
Mycobacterium leprae, an obligate intracellular parasite
that affects mainly skin and peripheral nerves (1). Although
the number of new cases of leprosy is decreasing, the
disease still constitutes a major public health problem in
many developing countries (2).
The clinical spectrum of leprosy is characterized by two
stable polar forms of disease. At one pole, tuberculoid
leprosy, the host is able to keep the disease under control
due to an efficient T-cell-mediated immune response; while
at the opposite pole, lepromatous leprosy, cell-mediated
immunity is inefficient leading to excessive bacillary multi-
plication and dissemination (3). Between the two stable
poles are unstable forms of leprosy, named borderline (or
dimorphous) that may combine characteristics of the polar
forms. Acute inflammatory events, known as reactional
episodes, may occur during the chronic course of leprosy,
due to either alterations in cellular immunity (type 1 or
reversal reaction) or excessive formation of immune com-
plexes at the sites of antigen deposition (type 2 or ery-
thema nodosum leprosum) (4).
Leprosy patients can present a great variability of signs
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and symptoms including arthralgia and arthritis similar to
that seen in rheumatic diseases, especially in rheumatoid
arthritis (RA) (5-7). The articular involvement in leprosy is
considered to be the third most frequent manifestation,
after dermatological and neurological involvement. Articu-
lar manifestations are reported in frequencies ranging from
1 to 78% (8,9).
Rheumatoid factor (RF) is reported as positive in 70-
80% of RA patients; however, its specificity is limited since
RF is also detected in sera from healthy elderly individuals
and patients with various other autoimmune and infectious
diseases, including leprosy (10-13). Although RF presents
limited specificity, it is widely used as a diagnostic marker
for RA. In contrast, anti-cyclic citrullinated peptide (anti-
CCP) antibodies display a high specificity (98-100%) for
RA (14,15), associated with a reasonable sensitivity (67-
74%) (16,17).
Anti-CCP antibodies have been evaluated in a large
number of patients with different autoimmune (16,18-21)
and infectious diseases (16,21-24). More recently, a high
frequency (32%) of anti-CCP antibodies was reported in
patients with active lung tuberculosis (24) and another
study showed a low frequency of anti-CCP among patients
with leprosy, a disease caused by another mycobacterium
(25).
The purpose of the present study was to evaluate the
usefulness of anti-CCP antibodies and IgM RF in distin-
guishing patients with leprosy-related articular involve-
ment from those with RA.
Patients and Methods
The leprosy group was constituted by 158 patients
seen at the Tropical Dermatology and Venereal Clinic of
Alfredo da Matta Foundation (Manaus, Brazil) from July
2004 to October 2006. Seventy-six patients with articular
involvement, characterized by the presence of either ar-
thralgia (pain) or arthritis (pain and joint swelling), and 82
gender- and age-matched patients without articular in-
volvement were studied. Leprosy diagnosis was performed
according to Ridley and Jopling classification criteria (3).
Careful physical exams and histories as well as medical
chart review and rheumatological examinations were per-
formed for all patients by two rheumatologists (S.L.E.R.
and H.L.A.P.), and leprosy patients with any concomitant
rheumatic disease were excluded.
The RA group comprised 69 patients fulfilling the Ameri-
can College of Rheumatology revised criteria for RA clas-
sification (26). The control group was composed by 89
healthy gender- and age-matched individuals to the lep-
rosy group, living in the same city.
The study was approved by both Institutional Review
Boards and all participants signed informed consent forms
and provided blood samples for laboratory tests. All serum
samples were stored at -20°C.
Detection of anti-CCP antibodies
Anti-CCP antibodies were detected by a second-gen-
eration ELISA using a commercial kit (Immunoscan RA
Anti-CCP test kit; EuroDiagnostica, Sweden), according to
manufacturer instructions. In brief, serum samples diluted
1:50 in sample diluent were distributed in microtiter plates
and incubated for 60 min at room temperature. After wash-
ing, the plates were incubated for 30 min at room temper-
ature with the ready-to-use peroxidase conjugated anti-
human IgG antibody provided by the kit. After washing, the
reaction was developed for 30 min at room temperature
with TMB solution, stopped with phosphoric acid and read
at 450 nm in a plate reader (Multiscan MS, Labsystems,
Finland). Pre-diluted anti-CCP standards as well as posi-
tive and negative controls were included in each plate. A 4-
parameter curve fit was used to calculate anti-CCP anti-
body levels in serum samples. Anti-CCP antibodies were
considered to be positive when above the cut-off level of
the kit (≥25 U/mL). The anti-CCP test used shows 75.1%
sensitivity for RA diagnosis, according to the manufac-
turer.
Rheumatoid factor
IgM RF was detected by the semi-quantitative latex
agglutination test with a commercial kit (RapiTex RF, Ger-
many). According to the manufacturer, IgM RF was consid-
ered to be positive when the serum titer was ≥1/4 (80 IU/
mL).
Statistical analysis
The Mann-Whitney and Kruskal-Wallis tests were used
for comparing age distribution among groups. The chi-
square test was used to compare the gender distribution,
and anti-CCP antibodies and RF frequencies between
groups. P values < 0.05 were considered to be statistically
significant. Statistical analysis was performed with the
SSPS-10 software.
Results
Among leprosy patients, 113 (71.5%) were male and
45 (28.5%) were female (P = 0.001). Among 76 patients
with articular involvement, 61 (80.3%) presented polyar-
thritis and 15 (19.7%) presented polyarthralgia. According
to the clinical classification, lepromatous leprae was the
most frequent form of leprosy, found in 38.2% of the
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patients with articular involvement and in 32.9% of the
patients without articular involvement. Regarding specific
treatment, 40.5% of leprosy patients were receiving poly-
chemotherapy and 59.5% had finished polychemothera-
py. Reactional episodes were present in 36.7% of the
leprosy patients (Table 1).
No differences were found between leprosy patients
with and without articular involvement in terms of gender,
age, clinical classification, use of specific medication or
occurrence of reactional episodes (Table 1).
The RA group was composed of 62 women and 7 men
(mean age of 45.3 ± 13.0 years and mean disease duration
of 115.77 ± 99.44 months). The gender and age distribu-
tions of the RA group differed from the leprosy and control
groups.
The healthy control group was com-
posed of 66 males and 23 females, with
mean age of 41.6 ± 14.63 years (range, 19
to 77 years). The age and gender distribu-
tions of this group were similar to the lep-
rosy group.
Anti-CCP antibodies were detected in
56 (81.2%) of the 69 RA patients and in
only 4 (2.5%) of the 158 leprosy patients,
none of them with articular involvement.
IgM RF was detected in 62.3% of RA pa-
tients and in only 2 (1.3%) leprosy pa-
tients, both with polyarthritis (Table 2). No
significant difference was found between
leprosy patients with and without articular
involvement regarding the frequency of
anti-CCP antibodies and IgM RF.
Among healthy controls, 3 individuals
(3.4%) were anti-CCP positive; 2 of them
with low to moderate titers (44 and 53 U/
mL) and the third one with a high titer
(1827 U/mL). Regarding IgM RF, we also
found 3 positive individuals, 2 with low
titers of IgM RF (80 IU/mL) and 1 with a
high titer of IgM RF (1280 IU/mL). Only 1
control presented high titers of anti-CCP
and IgM RF.
Figure 1 shows the distribution of anti-
CCP titers among patients with leprosy
(with and without articular involvement),
healthy controls and RA patients (IgM RF-
positive and -negative).
Regarding RA diagnosis, the specific-
ity of anti-CCP was similar to IgM RF (97.2
and 98%, respectively). However, the sen-
sitivity of anti-CCP was significantly higher
Table 1. Demographic characteristics, specific treatment and reactional episodes
of 158 leprosy patients with and without articular involvement (AI).
Characteristics of Leprosy with AI Leprosy without AI
patients (N = 158) (N = 76, 48%) (N = 82, 52%)
Age (mean ± SD in years) 39.88 ± 15.77 39.77 ± 14.80
Gender
Male 51 (67%) 62 (76%)
Female 25 (33%) 20 (24%)
Polyarthritis 61 (80%) 0 (0%)
Polyarthralgia 15 (20%) 0 (0%)
Clinical classification
Indeterminate leprosy 2 (3%) 2 (2%)
Tuberculoid 2 (3%) 4 (5%)
Tuberculoid borderline 16 (21%) 16 (20%)
Borderline borderline 12 (16%) 13 (16%)
Lepromatous borderline 15 (20%) 20 (24%)
Lepromatous 29 (38%) 27 (33%)
Current specific treatment
None (treated) 50 (66%) 44 (54%)
Polychemotherapy 26 (34%) 38 (46%)
Reactional episodes
Present 24 (32%) 34 (42%)
Absent 52 (68%) 48 (59%)
Data are reported as number of patients with percent in parentheses.
Table 2. Prevalence of anti-CCP antibodies and IgM RF in the serum of leprosy
and rheumatoid arthritis patients and healthy controls.
Variable Leprosy with Leprosy without Rheumatoid arthritis Controls
AI (N = 76) AI (N = 82) (N = 69) (N = 89)
Anti-CCP 0 (0%) 4 (5%) 56 (81%) 3 (3%)
IgM RF 2 (3%)* 0 (0%) 43 (62%) 3 (3%)
Data are reported as number of patients with percent in parentheses. AI = articular
involvement; Anti-CCP = anti-cyclic citrullinated peptide antibodies; RF = rheuma-
toid factor. *Both patients had polyarthritis.
than IgM RF (81.2 and 62.3%, respectively, P = 0.012).
Discussion
In the present study, both anti-CCP antibodies and IgM
RF proved to be equally useful and specific to distinguish
between leprosy with articular involvement and RA. How-
ever, anti-CCP was found to be more sensitive than IgM
RF.
The anti-CCP positivity found among RA patients in the
present study is in agreement with Dubucquoi et al. (27),
who reported a sensitivity of 85%. The anti-CCP2 test used
in our study has higher sensitivity than the anti-CCP1 test
(28).
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Articular involvement is the third major clinical com-
plaint in leprosy patients, justifying the necessity for a
differential diagnosis between leprosy and RA. The great
variability of the frequency of articular involvement re-
ported in the literature (8,9) is probably due to differences
in the number of patients studied and in the patient selec-
tion criteria.
Leprosy patients can present symmetrical polyarthritis
of small joints of hands and feet, mimicking RA, and
making the diagnosis of leprosy difficult, particularly when
this is the first disease manifestation (7,29).
The difference regarding gender distribution between
leprosy and RA was mainly due to the female predomi-
nance in RA while leprosy is more frequent in males.
Although the usual RA female:male ratio is 3:1, in our study
this ratio was higher because we included a group of RA
female patients evaluated in another study.
There is only one study in the literature addressing the
frequency of anti-CCP antibodies in leprosy. The authors
studied 64 patients and found only 2 positive cases, both
without articular symptoms. However, the number of pa-
tients with leprosy-related arthritis was not reported in this
study (25). In agreement with the former study, we also
found a low frequency of anti-CCP antibodies among 158
leprosy patients, without association with articular involve-
ment.
The frequency of IgM RF among leprosy patients was
also similar to that observed among healthy controls, and
in agreement with several studies (11,30,31) that reported
RF frequencies ranging from 0.5 to 13.8% among leprosy
patients. However, other studies have reported high fre-
quencies of RF in leprosy, varying from 35 up to 60%
(5,10,12,32). This discrepancy could be explained partially
by a number of factors, including the type of assay utilized,
study population, and possible role of different treatment
regimens (31). Abe et al. (10) and Petchclai et al. (30)
evaluated the frequency of RF in leprosy patients using the
latex and Waaler Rose tests, and they found higher RF
positivity with the Waaler Rose than with the latex test. In
contrast, these same authors found that the latex test was
more sensitive in RA patients than the other test. In agree-
ment with the results of Atkin et al. (5), we did not find an
association between RF and articular involvement. In con-
trast, Dhople (33) reported a high frequency of RF in
leprosy patients with arthritis and suggested that RF could
play a role in the pathogenesis of arthritis in acute leprous
reaction. However, the group of leprosy patients in that
study was very small.
The specificity of anti-CCP antibodies for RA has been
established in several studies including other autoimmune
and infectious diseases (16,18-23). This is the first study
designed to evaluate anti-CCP antibodies in a large num-
ber of leprosy patients either with (N = 76) or without (N =
82) articular involvement. Another study (25), a brief com-
munication, addressed the detection of anti-CCP anti-
bodies in 64 leprosy patients selected on the basis of the
stable polar forms of the disease. Although Elkayam et al.
(24) reported a high frequency (32%) of anti-CCP anti-
bodies in patients with active lung tuberculosis, an infec-
tious disease caused by Mycobacterium tuberculosis, it
was not clear if this reactivity was directed against citrullin-
ated or non-citrullinated epitopes present in the substrate
of the test. In leprosy patients, another mycobacterial
infectious disease, we found a low frequency of anti-CCP,
comparable to the healthy control group.
In contrast to the high prevalence of RF (62%) in
Figure 1. Serum anti-cyclic citrullinated pep-
tide (anti-CCP) antibody concentrations in
rheumatoid arthritis (RA) patients with (RF+, N
= 43) and without (RF-, N = 26) rheumatoid
factor, leprosy patients with (AI+, N = 76) and
without (AI-, N = 82) articular involvement mani-
festations and healthy controls (N = 89).
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tuberculosis obtained by Elkayam et al. (24) with ELISA,
Rapoport et al. (31) found less than 2% RF positivity in
tuberculosis and less than 0.5% in leprosy using the latex
test.
It is curious that in the present study one healthy
woman with no symptoms and no family history of autoim-
mune disease presented high titers of IgM RF and anti-
CCP antibodies. One possibility is that in the future this
woman will develop RA, in accordance with previous stud-
ies that found auto-antibodies in RA patient sera many
years before disease manifestation (15,28).
In addition to confirming the good positive predictive
values of the anti-CCP assay and RF latex test for RA, the
present study shows that both assays can be useful in
distinguishing patients with leprosy-induced arthritis from
patients with RA.
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